Immunogenicity of 2019-nCoV inactivated vaccine in children aged 3-11 years
10.3760/cma.j.cn112338-20230407-00221
- VernacularTitle:3~11岁儿童接种新型冠状病毒灭活疫苗的免疫原性研究
- Author:
Xiaodong LIU
1
;
Haidong LIU
;
Ping XIONG
;
Zhen LI
;
Jing LI
;
Jianwen SUN
;
Qingfan CAO
;
Li ZHANG
;
Qing XU
Author Information
1. 山东省疾病预防控制中心，济南 250014
- Keywords:
2019-nCoV inactivated vaccine;
Children;
Immunogenicity
- From:
Chinese Journal of Epidemiology
2023;44(11):1744-1747
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the immunogenicity to prototype strain of 2019-nCoV and cross immune response to its variants in children aged 3-11 years after completing the primary immunization of a 2019-nCoV inactivated vaccine for 28-42 days.Methods:From January to July 2022, children aged 3-11 years who had been vaccinated with 2019-nCoV inactivated vaccine according to the (0, 28) day immunization schedule were recruited in Rushan, Shandong Province. On 28-42 days after the primary immunization, venous blood samples (3 ml) were collected from them for the detections of the levels of neutralizing antibody to prototype strain, Beta variant, Gamma variant and Delta variant and the neutralizing antibody positive rates and GMTs were calculated.Results:A total of 395 children were included in the immunogenicity analysis, including 212 children aged 3-5 years and 183 children aged 6-11 years. The positive rates of neutralizing antibody to prototype strain, Beta, Gamma, and Delta variants on 28-42 days after the primary immunization were 100.00%, 74.68%, 99.24%, and 97.22%, respectively, there were no significant differences between two age groups ( P>0.05). On 28-42 days after the primary immunization, the GMTs of neutralizing antibody to prototype strain, Beta , Gamma and Delta variants were 168.19, 10.51, 53.65, and 31.10, respectively, the differences between two age groups were not significant ( P>0.05). Conclusion:The immunization with 2 doses of 2019-nCoV inactivated vaccine in 3-11 years old children showed good immunogenicity and produced certain cross protection to 2019-nCoV variants.
